SHR‐1316, an anti‐PD‐L1 antibody, plus chemotherapy as the first‐line treatment for advanced esophageal squamous cell carcinoma: A multicentre, phase 2 study

SHR‐1316, an anti‐PD‐L1 antibody, plus chemotherapy as the first‐line treatment for advanced esophageal squamous cell carcinoma: A multicentre, phase 2 study

Abstract Background This multicentre, open‐label study evaluated the efficacy and safety of antiprogrammed death ligand 1 antibody SHR‐1316 plus liposomal irinotecan and 5‐fluorouracil as the first‐line treatment for patients with advanced esophageal squamous cell carcinoma (ESCC). Methods Eligible...

Full description

Bibliographic Details
Main Authors:	Lan Mu, Yan Song, Kuaile Zhao, Ying Liu, Qingxia Fan, Xi Wang, Qun Li, Xiaopeng Wang, Jing Huang
Format:	Article
Language:	English
Published:	Wiley 2021-05-01
Series:	Thoracic Cancer
Subjects:	anti‐PD‐L1 antibody chemotherapy esophageal squamous cell carcinoma liposomal irinotecan
Online Access:	https://doi.org/10.1111/1759-7714.13913

Similar Items

Rh-Endostatin Plus Irinotecan/Cisplatin as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma: An Open-Label, Phase II Study
by: Chang, J., et al.
Published: (2022)

Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial
by: Jing Huang, et al.
Published: (2019-04-01)

Comparison of PD-1 Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma in the Second-Line Setting
by: Yi-Xin Zhou, et al.
Published: (2021-09-01)

PD-L1 expression and its clinicopathological correlation in advanced esophageal squamous cell carcinoma in a Chinese population
by: Lulu Rong, et al.
Published: (2019-01-01)

Prognostic Significance of Serum PD-L1 Level in Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Treated with Combination Cytotoxic Chemotherapy
by: Fu R, et al.
Published: (2021-06-01)

Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Negative Patient With Refractory Metastatic Esophageal Squamous Cell Carcinoma: A Case Report and Literature Review
by: Xiangrong Zhao, et al.
Published: (2020-09-01)

Combination Chemo‐Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti‐PD‐1
by: Xiangsheng Liu, et al.
Published: (2021-03-01)

Phenotypic profiling and prognostic significance of immune infiltrates in esophageal squamous cell carcinoma
by: Chuqing Pan, et al.
Published: (2021-01-01)

Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR‐1210), a novel anti‐PD‐1 antibody
by: Xi Wang, et al.
Published: (2019-06-01)

Addition of camrelizumab to docetaxel, cisplatin, and radiation therapy in patients with locally advanced esophageal squamous cell carcinoma: a phase 1b study
by: Wencheng Zhang, et al.
Published: (2021-01-01)

Characterization of the Oral and Esophageal Microbiota in Esophageal Precancerous Lesions and Squamous Cell Carcinoma
by: Zhengqi Li, et al.
Published: (2021-09-01)

A nomogram-based immunoprofile predicts overall survival for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy
by: Jingjing Duan, et al.
Published: (2018-10-01)

PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma
by: Dagmar Kollmann, et al.
Published: (2018-06-01)

Positive Programmed Cell Death-Ligand 1 Expression Predicts Poor Treatment Outcomes in Esophageal Squamous Cell Carcinoma Patients Receiving Neoadjuvant Chemoradiotherapy
by: Wan-Ting Huang, et al.
Published: (2019-11-01)

Interactive Effects of PD-L1 Expression in Tumor and Immune Cells on Prognosis of Esophageal Squamous Cell Carcinoma: A One-Center Retrospective Cohort Study
by: Shi F, et al.
Published: (2020-07-01)

Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma
by: Wei Guo, et al.
Published: (2021-05-01)

A comparative study of cisplatin-based definitive chemo-radiation in non-metastatic squamous cell carcinoma of the esophagus
by: Bahram Mofid, et al.
Published: (2016-10-01)

Irinotecan Plus Doxorubicin Hydrochloride Liposomes for Relapsed or Refractory Wilms Tumor
by: Juan Wang, et al.
Published: (2021-09-01)

Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer
by: Li-Tzong Chen, et al.
Published: (2019-07-01)

MiR-433-3p Inhibits Proliferation and Invasion of Esophageal Squamous Cell Carcinoma by Targeting GRB2
by: Qizhong Shi, et al.
Published: (2018-04-01)

A prognostic model for stratification of stage IB/IIA esophageal squamous cell carcinoma: a retrospective study
by: Lei-Lei Wu, et al.
Published: (2021-02-01)

Truth telling for patients with esophageal squamous cell carcinoma in Henan, China
by: Lian-Qun Zhang, et al.
Published: (2017-01-01)

A study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin for advanced esophageal squamous cell carcinoma with T4 and/or M1 lymph node metastasis or locoregional recurrence
by: Qi Liu, et al.
Published: (2020-04-01)

Efficacy and safety of apatinib treatment for advanced esophageal squamous cell carcinoma
by: Li J, et al.
Published: (2017-08-01)

Inducing multiple antibodies to treat squamous cell esophageal carcinoma
by: Isamu Hoshino, et al.
Published: (2020-10-01)

Cross sectional study of serum selenium concentration and esophageal squamous dysplasia in western Kenya
by: Natalie R. Pritchett, et al.
Published: (2017-12-01)

Long-term outcome of irradiation with or without chemotherapy for esophageal squamous cell carcinoma: a final report on a prospective trial
by: Liu Mina, et al.
Published: (2012-08-01)

Esophageal Squamous Cell Carcinoma with Marked Eosinophil Infiltration
by: Minoru Fukuchi, et al.
Published: (2011-11-01)

Case Report: Primary and Acquired Resistance Mechanisms of Nimotuzumab in Advanced Esophageal Squamous Cell Carcinoma Revealed by Targeted Sequencing
by: Dantong Sun, et al.
Published: (2020-10-01)

Post treatment NLR is a predictor of response to immune checkpoint inhibitor therapy in patients with esophageal squamous cell carcinoma
by: Xianbin Wu, et al.
Published: (2021-07-01)

Ultrasound-Stimulated Microbubbles Inhibit Aggressive Phenotypes and Promotes Radiosensitivity of esophageal squamous cell carcinoma
by: Jinjun Shi, et al.
Published: (2021-01-01)

The Prognosis and Feasibility of Extensive Clinical Target Volume in Postoperative Radiotherapy for Esophageal Squamous Cell Carcinoma: A Phase II Clinical Trial
by: Xiaofei Zhang, et al.
Published: (2021-07-01)

Comprehensive Analysis and Identification of Key Driver Genes for Distinguishing Between Esophageal Adenocarcinoma and Squamous Cell Carcinoma
by: Feng Wang, et al.
Published: (2021-05-01)

Inhibitory Role of Pentraxin-3 in Esophageal Squamous Cell Carcinoma
by: Dan Ma, et al.
Published: (2016-01-01)

Helicobacter Pylory infection in patients with esophageal squamous cell carcinoma
by: Omer Bilgehan Poyrazoglu, et al.

Metastatic squamous cell carcinoma of colon from esophageal cancer
by: Natasha Garg, et al.
Published: (2017-04-01)

Prognostic significance of preoperative IKBKE expression in esophageal squamous cell carcinoma
by: Yang WJ, et al.
Published: (2018-03-01)

Risk factors for esophageal fistula in thoracic esophageal squamous cell carcinoma invading adjacent organs treated with definitive chemoradiotherapy: a monocentric case-control study
by: Takeshi Kawakami, et al.
Published: (2018-05-01)

An Entirely Atypical Presentation of Esophageal Squamous Cell Cancer with Pancreatic and Bone Metastases
by: Eric Yoon, et al.
Published: (2019-10-01)

Immunohistochemical prognostic markers of esophageal squamous cell carcinoma: a systematic review
by: Chunni Wang, et al.
Published: (2017-08-01)